Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LEO 134310 vehicle is the pharmacologically inactive cutaneous solution used as a placebo control in clinical trials for LEO 134310. LEO 134310, developed by LEO Pharma, is a non-steroidal, selective glucocorticoid receptor (GR) agonist designed as a "dual-soft" ligand that is rapidly deactivated in the blood and liver to minimize systemic side effects. The vehicle formulation is used in Phase 1 studies to provide a baseline for evaluating the safety, tolerability, and efficacy of the active compound in patients with chronic plaque psoriasis. It is designed to match the physical and delivery characteristics of the active drug without containing the active pharmaceutical ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LEO 134310 vehicle.